17 January 2019

Bart-Jan Kullberg is nominated for the ZonMw Medical Inspirator Award. You can vote till 11 February.

This prize is awarded for the most inspiring collaboration between patients and medical researchers. Bart-Jan Kullberg works with patients' representatives to measure long-term outcomes of Lyme disease as a tool to select new therapeutic modalities. 

For more information follow this link to the ZonMw website (in Dutch). For voting click here.

Bart-Jan Kullberg is member of theme Infectious diseases and global health.

Related news items


The impact of sex and gender in the COVID-19 pandemic

29 May 2020

This case study by Sabine Oertelt-Prigione and developed by the European Commission’s H2020 Expert Group to update and expand "Gendered Innovations/ Innovation through Gender", examines the impact of sex and gender in the current COVID-19 pandemic.

read more

Terrestrial bacteria can grow on nutrients from space

26 May 2020

Researchers from the Radboudumc describe in an article in Astrobiology that bacteria can survive on an 'extraterrestrial diet', which affected their pathogenic potential.

read more

The new front line: big data podcast

22 May 2020

What role do big data and technology play in the fight against corona? What data can help save lives? How do you ensure that your personal health data is used safely? Among others, Peter-Bram 't Hoen explains.

read more

OARSI Basic Science Award for Peter van der Kraan

22 May 2020

Purpose of this Basic Science Award of the Osteoarthritis Research Society International (OARSI) is to stimulate fundamental research in the field of osteoarthritis.

read more

Evaluation of an AI system for detection of COVID-19 on Chest X-Ray images

22 May 2020

In the journal Radiology researchers from Radboudumc, Bernhoven Hospital and Jeroen Bosch Hospital described how an artificial intelligence system (CAD4COVID-XRay) can identify characteristics of COVID-19 on chest x-rays with performance comparable to six independent radiologists.

read more

First clinical trial with genetically modified malaria vaccine completed

22 May 2020

In an innovative study, Radboudumc and LUMC jointly tested a candidate vaccine based on a genetically weakened malaria parasite. The results of this clinical trial, published in Science Translational Medicine, show that the vaccine is safe and elicits a defense response against a malaria infection.

read more